A detailed history of Ubs Group Ag transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 13,118 shares of CAPR stock, worth $190,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,118
Previous 8,687 51.01%
Holding current value
$190,735
Previous $41,000 385.37%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.56 - $15.21 $15,774 - $67,395
4,431 Added 51.01%
13,118 $199,000
Q2 2024

Aug 13, 2024

BUY
$4.63 - $7.09 $33,275 - $50,955
7,187 Added 479.13%
8,687 $41,000
Q1 2024

May 13, 2024

BUY
$3.61 - $6.88 $5,415 - $10,320
1,500 New
1,500 $10,000
Q1 2023

May 12, 2023

BUY
$3.78 - $5.03 $16,779 - $22,328
4,439 New
4,439 $18,000
Q2 2022

Aug 10, 2022

BUY
$2.89 - $4.51 $64,915 - $101,303
22,462 Added 326.01%
29,352 $102,000
Q1 2022

May 16, 2022

BUY
$2.83 - $5.68 $8,891 - $17,846
3,142 Added 83.83%
6,890 $23,000
Q4 2021

Feb 14, 2022

BUY
$2.89 - $4.16 $10,831 - $15,591
3,748 New
3,748 $11,000
Q3 2021

Nov 15, 2021

SELL
$3.8 - $5.23 $7,303 - $10,052
-1,922 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$3.16 - $5.72 $4,888 - $8,848
1,547 Added 412.53%
1,922 $10,000
Q1 2021

May 12, 2021

SELL
$3.63 - $7.93 $17,064 - $37,278
-4,701 Reduced 92.61%
375 $2,000
Q4 2020

Feb 11, 2021

BUY
$3.43 - $5.23 $10,893 - $16,610
3,176 Added 167.16%
5,076 $17,000
Q3 2020

Nov 12, 2020

BUY
$4.08 - $9.81 $3,672 - $8,829
900 Added 90.0%
1,900 $10,000
Q2 2020

Jul 31, 2020

SELL
$1.0 - $8.5 $439 - $3,731
-439 Reduced 30.51%
1,000 $5,000
Q1 2020

May 01, 2020

SELL
$0.94 - $2.02 $3,735 - $8,027
-3,974 Reduced 73.42%
1,439 $2,000
Q4 2019

Feb 14, 2020

BUY
$1.04 - $3.55 $5,365 - $18,314
5,159 Added 2031.1%
5,413 $7,000
Q3 2019

Nov 14, 2019

BUY
$2.38 - $6.23 $604 - $1,582
254 New
254 $1,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $354M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.